<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7858">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03004638</url>
  </required_header>
  <id_info>
    <org_study_id>D5780C00005</org_study_id>
    <nct_id>NCT03004638</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease</brief_title>
  <official_title>A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety pharmacokinetics, and pharmacodynamics of repeat weekly dosing of
      MEDI6012 in subjects with stable atherosclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety,
      Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of MEDI6012 in Subjects
      with Stable Atherosclerotic Cardiovascular Disease
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Anticipated">November 14, 2017</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability of MEDI6012</measure>
    <time_frame>Day 1 to Day 71</time_frame>
    <description>Measured by the incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of MEDI6012 subjects with treatment-emergent AEs related to 12-lead ECG</measure>
    <time_frame>Day 1 to Day 71</time_frame>
    <description>ECG parameters will be assessed and summarized descriptively by treatment group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of MEDI6012 subjects with treatment-emergent AEs related to vital signs</measure>
    <time_frame>Day 1 to Day 71</time_frame>
    <description>Vital signs results will be summarized using descriptive statistics at each time point by treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of MEDI6012 subjects with treatment-emergent AEs related to laboratory results</measure>
    <time_frame>Day 1 to Day 71</time_frame>
    <description>Clinical laboratory results including serum chemistry, hematology, and others will be summarized using descriptive statistics at each time point by treatment group with placebo group combined. Change in baseline to each post baseline time point in these data will also be summarized, where appropriate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline adjusted area under the curve</measure>
    <time_frame>Time 0 to 96 hours post dose 3</time_frame>
    <description>Baseline adjusted HDL-C, HDL-CE, and CE AUC will be calculated using the trapezoidal rule. Statistical comparison between treatment groups with placebo groups combined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Cmax</measure>
    <time_frame>Day 0 and Day 28 post last dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity rate</measure>
    <time_frame>Day 0 to Day 71</time_frame>
    <description>ADA incidence rate and titer will be tabulated for each treatment group. Samples confirmed positive for ADA will be tested and analyzed for nAB titer and summarized similarly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline adjusted area under the curve</measure>
    <time_frame>Time 0 to 96 hours post last dose</time_frame>
    <description>Baseline adjusted Apolipoprotein A,LDL, and Apolipoprotein B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Tmax</measure>
    <time_frame>Day 0 and Day 28 post last dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 AUC</measure>
    <time_frame>Day 0 and Day 28 post last dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MEDI6012 Terminal Half life</measure>
    <time_frame>Day o and Day 28 post last dose</time_frame>
    <description>Non-compartmental analysis will be performed for MEDI6012 treated subjects. Descriptive statistics for PK parameters will be provided</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 cohort 1 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 cohort 2 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI6012 Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI6012 cohort 3 dose level</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI6012</intervention_name>
    <description>MEDI6012</description>
    <arm_group_label>MEDI6012 Cohort 1</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 2</arm_group_label>
    <arm_group_label>MEDI6012 Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 mL</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-childbearing potential

          -  Diagnosis of stable atherosclerotic CVD

          -  Currently receiving a stable dose of Statin

        Exclusion Criteria:

          -  Unstable cardiovascular condition within 3 months of screening

          -  Elective arterial revascularization with in the past month

          -  Any planned arterial revascularization

          -  Body mass index &lt;18 or &gt;45

          -  Clinically significant ECG that may interfere with the interpretation of serial ECG
             and QT interval changes at screening

          -  Chronic kidney disease defined by estimated glomerular filtration rate of less than
             30 mL/mim/1.73m2

          -  Triglycerides greater than 500 mg/dL, LDL-C greater than 160 mg/dL, or HDL-C greater
             than 60 for males, or 65 for females

          -  Clinically significant vital sign abnormalities

          -  Genetic disorder of cholesterol metabolism

          -  History of overt liver disease

          -  Poorly controlled endocrine disorder (Diabetes or Thyroid disorder)

          -  Current or recent use of systemic corticosteroids

          -  Recent or ongoing infection or febrile illness

          -  History of active malignancy within 5 years

          -  History of alcohol or recreational substance abuse in the past 6 months

          -  Concurrent enrollment in another clinical study of any investigational drug therapy
             or use of any biologicals within 6 months prior to screening or within 5 half-lives
             of an investigational agent or biologic, whichever is longer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 23, 2017</lastchanged_date>
  <firstreceived_date>December 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>CAD</keyword>
  <keyword>Atherosclerotic Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
